Arthur Holden, Shaf Yousaf, Jurgen Schwiezer, Severin Schwan, Franz Humer, Melanie Mahtani , Patrick Sullivan, Christopher Maki | GenomeWeb
Arthur Holden plans to leave his post as vice president of corporate and market development at Illumina in mid-October, the company said last week in a filing with the US Securities and Exchange Commission.
 
Holden is director of the Serious Adverse Events Consortium, a pharma-backed initiative announced last week that aims to find genetic causes for severe adverse events that hamper drug development.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.